[go: up one dir, main page]

WO2006001029A3 - Antiretroviral compositions - Google Patents

Antiretroviral compositions Download PDF

Info

Publication number
WO2006001029A3
WO2006001029A3 PCT/IN2004/000184 IN2004000184W WO2006001029A3 WO 2006001029 A3 WO2006001029 A3 WO 2006001029A3 IN 2004000184 W IN2004000184 W IN 2004000184W WO 2006001029 A3 WO2006001029 A3 WO 2006001029A3
Authority
WO
WIPO (PCT)
Prior art keywords
nevirapine
lamivudine
zidovudine
present
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2004/000184
Other languages
French (fr)
Other versions
WO2006001029A2 (en
Inventor
Reddy Pothireddy Venkateswar
Muppidi Vanaja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Drugs Ltd
Original Assignee
Hetero Drugs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Drugs Ltd filed Critical Hetero Drugs Ltd
Priority to PCT/IN2004/000184 priority Critical patent/WO2006001029A2/en
Publication of WO2006001029A2 publication Critical patent/WO2006001029A2/en
Publication of WO2006001029A3 publication Critical patent/WO2006001029A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides stable pharmaceutical formulations for a combination product of zidovudine, lamivudine and nevirapine. Thus, for example, the present invention provides a stable tablet formulation comprising zidovudine, lamivudine, nevirapine, microcrystalline cellulose, starch, croscarmellose sodium, polyvinylpyrrolidone, magnesium stearate, colloidal anhydrous silica, crospovidone and a coating of hydroxypropyl(methyl)cellulose.
PCT/IN2004/000184 2004-06-25 2004-06-25 Antiretroviral compositions Ceased WO2006001029A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000184 WO2006001029A2 (en) 2004-06-25 2004-06-25 Antiretroviral compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000184 WO2006001029A2 (en) 2004-06-25 2004-06-25 Antiretroviral compositions

Publications (2)

Publication Number Publication Date
WO2006001029A2 WO2006001029A2 (en) 2006-01-05
WO2006001029A3 true WO2006001029A3 (en) 2006-05-11

Family

ID=35782186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000184 Ceased WO2006001029A2 (en) 2004-06-25 2004-06-25 Antiretroviral compositions

Country Status (1)

Country Link
WO (1) WO2006001029A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0500586A (en) * 2005-02-21 2006-10-10 Fundacao Oswaldo Cruz pharmaceutical composition, process for preparing said composition, use of the composition thereof in the treatment of immunodeficiency caused by HIV infection and method of treatment thereof
RU2010117269A (en) * 2007-10-02 2011-11-10 Эмори Юнивёсити (Us) ACTIVE COMBINATIONS OF ZIDOVUDIN AND MEDICINES WHICH ARE SELECTIVE FOR THE K65R MUTATION IN HIV POLYMERASE
US20110117193A1 (en) * 2008-01-17 2011-05-19 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
US20110024043A1 (en) 2009-07-02 2011-02-03 Dexcom, Inc. Continuous analyte sensors and methods of making same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002498A1 (en) * 2002-06-27 2004-01-08 Glaxo Group Limited Antiviral regimens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002498A1 (en) * 2002-06-27 2004-01-08 Glaxo Group Limited Antiviral regimens

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANTIVIR THER., vol. 7, no. 2, June 2002 (2002-06-01), pages 81 - 90 *
ANTIVIR THER., vol. 9, no. 2, April 2004 (2004-04-01), pages 197 - 204 *
DATABASE MEDLINE [online] FRENCH M. ET AL: "Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study", Database accession no. 12032876 *
DATABASE MEDLINE [online] PLANA M. ET AL: "Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine", Database accession no. 15134181 *
DATABASE MEDLINE [online] PODZAMCZER D. ET AL: "A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)", Database accession no. 12212928 *
HIV CLIN. TRIALS, vol. 3, no. 3, May 2002 (2002-05-01) - June 2002 (2002-06-01), pages 177 - 185 *

Also Published As

Publication number Publication date
WO2006001029A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2003057151A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
WO2006131491A8 (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
AU2018335259A1 (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
MX337603B (en) COMPOSITIONS AND PHARMACEUTICAL TABLETS WITH COMPRESSIBLE COATING AND MANUFACTURING METHODS.
TW200730176A (en) Formulations of quinolinones
RS53570B1 (en) DPP IV INHIBITOR FORMULATIONS
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
PL372215A1 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
WO2010069795A3 (en) Capecitabine rapidly disintegrating tablets
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007106746A3 (en) Formulations for ecallantide
WO2008129517A3 (en) A stabilized delayed release pharmaceutical composition of rabeprazole
WO2003086362A3 (en) Method of stabilizing bupropion hydrochloride tablets
AU2002358676A1 (en) Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IS7208A (en) Oral oral form of administration
WO2007103867A3 (en) Tablet formulations and processes
AR033467A1 (en) COMPRESSED MELOXICAM DE RAPIDA DISGREGACION
WO2006001029A3 (en) Antiretroviral compositions
WO2010144339A3 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
DK1355906T3 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1429/CHENP/2004

Country of ref document: IN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase